Lilly's Incretin Dominance Trumps Merck's Patent Cliff Fears
Lilly and Merck are two pharmaceutical giants that recently reported their second quarter earnings. The results show a stark contrast between the two companies, with Lilly experiencing significant growth while Merck faces challenges due to the impending patent cliff for its key product, KEYTRUDA.
Lilly's revenue rose 47.7% year-over-year, driven by strong sales of Mounjaro and Zepbound. The company's CEO, Dave Ricks, said 'Lilly's momentum continues' as it raised its full-year guidance. Meanwhile, Merck's revenue growth was modest at 5%, with KEYTRUDA sales increasing just 4%. The company is racing to rebuild around the patent cliff for KEYTRUDA.
Lilly's strategy focuses on expanding its incretin franchise, which has shown significant growth and potential. On the other hand, Merck is relying on new launches, such as Lipvendra, an oral PCSK9 inhibitor targeting 30 million undertreated U.S. patients. However, this transition may take time, and Merck's rebuild efforts are still ongoing.